Oxigene plans on presenting more data from the phase II/III study of zybrestat in thyroid cancer next month and additional phase II lung cancer data in November. Oxigene shares closed Friday at 27 cents. --Written by Adam Feuerstein in Boston. >To contact the writer of this article, click here: Adam Feuerstein. >To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein. >To submit a news tip, send an email to: firstname.lastname@example.org.